MEDRAD is a worldwide market leading manufacturer and distributor of high tech medical devices that enable or enhance diagnostic and therapeutic medical procedures for computed tomography, magnetic resonance, and cardiovascular applications.
MEDRAD's E-Mail Education Bulletin will help you stay in touch with clinical and industry issues affecting medical imaging.
Subscribe today >>
MEDRAD has built a reputation for reliable products and customer support.
Read about MEDRAD's brand promise and view the Performance. For life. video >>
MEDRAD Interventional/Possis, the new endovascular-focused division of MEDRAD, announced that it is a sponsor of the ATTRACT trial which will evaluate the long-term benefits of using the company’s AngioJet® Rheolytic™ Thrombectomy System in combination with clot-softening drugs to provide more rapid endovascular treatment of Deep Vein Thrombosis (DVT).
MEDRAD announced that the Continuum Wireless version of its Continuum MR Infusion System has received U.S. Food and Drug Administration (FDA) 510(k) clearance. The new wireless option for control of medication infusion inside or outside the MR scan room will increase workflow efficiencies and throughput while enhancing clinician confidence.
Read >>
MEDRAD announced today the first installation of its Intego PET Infusion System at the University of Pittsburgh, Hillman Cancer Center. To achieve this milestone, MEDRAD partnered with IBA Molecular... Find out more >>
The new Intego™ PET Infusion System is the first infusion system available in the United States to automate the FDG delivery process. Read more >>
The agreement will enable health care providers to inject FDG for PET/CT imaging procedures in an innovative, new way. Full story >>
XDS™ Extravasation Detector Wins Medical Design Excellence AwardMEDRAD's XDS™ Extravasation Detector for the Stellant® CT Injection System has received a 2008 Medical Design Excellence Award® (MDEA). The XDS aids in the detection of leaking intravenous contrast media from the injection site into surrounding tissue during computed tomography (CT) diagnostic studies.
September 22, 2008
MEDRAD Interventional™/Possis® to Co-Sponsor ATTRACT Trial, Evaluating Long-Term Benefits of New Treatments for Deep Vein Thrombosis
September 12, 2008
Over 900 MEDRAD® Employees Volunteer Time, Resources Today
August 27, 2008
Confirma and MEDRAD Partner to Advance Patient Care in the European Union
August 11, 2008
MEDRAD® Receives FDA 510(k) Clearance for Wireless MR Infusion System
August 7, 2008
MEDRAD® Installs First Intego™ PET Infusion System
July 21, 2008
New MEDRAD® Facilities Earn Recognition as “Green” Buildings
Our College Career Fair Calendar is updated.
